Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA BiologicsADMA -2.50%64 Debt-to-Equity is 0.52 as of Mar. 2026, which is 50% below its 10-year median of 1.03. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.13 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, ADMA Biologics ranks worse than 75.78% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ADMA Biologics's Debt-to-Equity or its related term are showing as below:
ADMA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -132.03 Med: 1.03 Max: 5.72
Current: 0.52
During the past 13 years, the highest Debt-to-Equity Ratio of ADMA Biologics was 5.72. The lowest was -132.03. And the median was 1.03.
ADMA's Debt-to-Equity is ranked worse than 75.78% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs ADMA: 0.52
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ADMA Biologics Debt-to-Equity Related Terms
ADMA Biologics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Debt-to-Equity Comparison
For the Biotechnology subindustry, ADMA Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Debt-to-Equity of 0.52 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ADMA Biologics and its competitors. This is 50% below median its historical median of 1.03. According to the industry distribution chart, ADMA Biologics ranks #732 out of 966 companies in the Biotechnology industry, placing it in the top 75.8%.
Is ADMA Biologics' Debt-to-Equity too high?
ADMA Biologics' current Debt-to-Equity of 0.52 is 50% below median its 10-year median of 1.03. The Biotechnology industry median Debt-to-Equity is 0.16. ADMA Biologics' value of 0.52 is 225% above this industry median. Based on the distribution chart, ADMA Biologics ranks #732 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Debt-to-Equity compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #732 out of 966 companies for Debt-to-Equity. This places ADMA Biologics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. ADMA Biologics' value of 0.52 is 225% above this benchmark. While the company's 10-year median is 1.03 vs. the industry median of 0.16, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Debt-to-Equity of 0.52 is 225% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Debt-to-Equity is 0.52, which is 50% below median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.13, compared to a current price of $8.38 — trading 53.8% below its estimated fair value. The current Debt-to-Equity is 0.52, which is 50% below median its 10-year median of 1.03 and 225% above the Biotechnology industry median of 0.16. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Debt-to-Equity is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.38 is trading 53.8% below its estimated GF Value™ of $18.13.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Debt-to-Equity: 0.52 (50% below median its 10-year median of 1.03)
GF Value™: $18.13 vs. price of $8.38 (53.8% below fair value)
Industry Position: 225% above the Biotechnology median (#732 of 966)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
